FDA rejects Biohaven approval request for troriluzole, triggering R&D cost cutting
The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline in order to shrink its annual R&D spend by 60%.…